To the Editor:We are grateful for the insightful comments from the Letter to the Editor regarding our article titled “Prolonged Dysphagia following a COVID-19 Infection in a Patient with Parkinson’s Disease.” We would like to respond to their concerns as follows:The authors of the letter suggested three differential diagnoses as the cause of dysphagia in the patient discussed in our case report. First, the possibility of a subtype of Guillain-Barre syndrome may be unlikely. If severe oropharyngeal dysphagia occurs in any subtype of Guillain-Barre syndrome, cranial nerve IX or X involvement must be present. However, the patient in our study had no hoarseness, and his palatine arch elevation and gag reflex were normal.[1] In addition, there was no ophthalmoparesis or ataxia suggestive of Bickerstaff brainstem encephalitis. Although it would have been clearer if cerebrospinal fluid investigation and nerve conduction studies were conducted, we believe that Guillain-Barre syndrome was clinically unlikely.Ischemic stroke of the brainstem was also suspected because of immune-mediated hypercoagulability in COVID-19.[2] In this case, because only brain computed tomography was performed and there was no brain magnetic resonance imaging, it was difficult to completely rule out ischemic stroke.[1] As suggested in the letter, prolonged dysphagia could develop because of a small brainstem lesion not visible on computed tomography. In such a case, however, unilateral pharyngeal dysfunction, which was unlikely in our case, is usually detected in clinical examinations and a videofluoroscopic swallowing study. Although bilateral brainstem involvement may cause symmetric pharyngeal dysphagia, this is unlikely to happen without other neurological signs.The relationship between autonomic dysfunction and oropharyngeal dysphagia remains unclear. Although it is known that autonomic dysfunction can cause dysphagia, it is mainly associated with xerostomia or esophagus dysfunction.[3] Among patients with multiple system atrophy, which is often accompanied by oropharyngeal dysphagia, those with pure autonomic failure rarely present oropharyngeal dysphagia. There were no other symptoms suggestive of autonomic failure in this patient, such as tachycardia or bradycardia, hypohidrosis or hyperhidrosis, diarrhea or constipation, or ptosis. Therefore, there is insufficient evidence to consider dysautonomia as the cause of dysphagia in this patient.Although noninvasive neuromodulations could be promising treatment in patients with dysphagia, there has been no pivotal study to confirm their benefit in patients with Parkinson disease (PD) and were, therefore, not applied in this patient. To date, the use of repetitive transcranial magnetic stimulation, transcranial direct current stimulation, and pharyngeal electrical stimulation are not approved for the treatment of dysphagia in PD patients in our country. Only surface electrical stimulation has been approved for dysphagia treatment in patients with central nervous system disorders and cancer. However, surface electrical stimulation has shown a controversial effect on swallowing function in PD patients.[4] The National Health Insurance Service in our country usually does not cover the cost of surface electrical stimulation in PD patients with a disease duration of more than 2 yrs. Therefore, the use of surface electrical stimulation is limited in PD patients.We are thankful for the insightful comments and the identification of future research possibilities. Further investigation is necessary to evaluate the influence of COVID-19 in patients with PD.